The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade

Multiple Sclerosis

Volumn 21, Issue 9, 2015, Pages 1200-1203

  Kremer, David ^a   Förster, Moritz ^a   Schichel, Tanja ^a   Göttle, Peter ^a   Hartung, Hans Peter ^a   Perron, Hervé ^b   Küry, Patrick ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b GENEURO SA   (Switzerland)

Author keywords

Antibody; human endogenous retrovirus; multiple sclerosis associated retrovirus; Myelin repair; nitrosative stress; oligodendrocytes; regeneration; therapy

Indexed keywords

CRYOPROTECTIVE AGENT; MONOCLONAL ANTIBODY GNBAC1; MYELIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; ENVELOPE PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NEUTRALIZING ANTIBODY GNBAC1; RECOMBINANT HUMAN ENDOGENOUS RETROVIRUS TYPE W ENVELOPE PROTEIN; RECOMBINANT PROTEIN; TOLL LIKE RECEPTOR 4; GNBAC1 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY;

ANTIBODY DETECTION; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HUMAN ENDOGENOUS RETROVIRUS TYPE W; MOLECULAR DYNAMICS; NITROSATIVE STRESS; NONHUMAN; OLIGODENDROGLIA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROVIRIDAE; VIRUS NEUTRALIZATION; CLINICAL TRIAL (TOPIC); HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL LINE; CYTOLOGY; DRUG EFFECTS; ENDOGENOUS RETROVIRUS; VIROLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; CELL DIFFERENTIATION; CELL LINE; ENDOGENOUS RETROVIRUSES; HUMANS; OLIGODENDROGLIA; VIRAL ENVELOPE PROTEINS;

EID: 84985991340     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514560926     Document Type: Article

References (10)

1. Kremer D, Schichel T, Förster M,. Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation. Ann Neurol 2013; 74: 721-732.
2. Perron H, Lang A., The human endogenous retrovirus link between genes and environment in multiple sclerosis and in multifactorial diseases associating neuroinflammation. Clin Rev Allergy Immunol 2010; 39: 51-61.
3. Perron H, Garson JA, Bedin F,. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis. Proc Natl Acad Sci U S A 1997; 94: 7583-7588.
4. Perron H, Germi R, Bernard C,. Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler 2012; 18: 1721-1736.
5. Perron H, Jouvin-Marche E, Michel M,. Multiple sclerosis retrovirus particles and recombinant envelope trigger an abnormal immune response in vitro, by inducing polyclonal Vbeta16 T-lymphocyte activation. Virology 2001; 287: 321-332.
6. Rolland A, Jouvin-Marche E, Viret C,. The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses. J Immunol 2006; 176: 7636-7644.
7. Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, at al, A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. Mult Scler. 2014 12. pii: 1352458514554052. [Epub ahead of print].
8. Tao RR, Ji YL, Lu YM,. Targeting nitrosative stress for neurovascular protection: New implications in brain diseases. Curr Drug Targets 2012; 13: 272-284.
9. Akassoglou K, Bauer J, Kassiotis G,. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: Models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol 1998; 153: 801-813.
10. Solomon AJ, Spain RI, Kruer MC,. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler 2011; 17: 1472-1487.